Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Standard BioTools (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Standard BioTools (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. market close. The company develops standardized next-generation life science tools for biomedical research, provided for research use only and not for diagnostic procedures.
Details
Market move: LAB -7.43% in the Jul 22 session. 2Q26 earnings report
On Jul 22, the day this news came out, LAB closed 7.43% below the previous close. Argus tracked a trough of -5.1% from its starting point during tracking. Our momentum scanner recorded 10 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 22 session.
Key Figures
- Results date
- August 5, 2026
- Second quarter 2026 financial results after U.S. market close
Previous Earnings date Reports
-
First-quarter results scheduled for release after U.S. market close
-
Fourth-quarter and full-year results scheduled for February 24
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
research use only technical
limited use label license regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.
About Standard BioTools Inc.
Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
ir@standardbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.